Endocrine Abstracts

Background and aims: To describe the characteristics of patients with non-controlled type 2 diabetes mellitus with liraglutide treatment.

Materials and methods: Retrospective descriptive study. 85 outpatients (women 49, ages 18–86 years old with non-controlled type 2 diabetes mellitus) were evaluated between July 2013 and March 2014 and received treatment with liraglutide 1.8 mg SQ/day (0.6 mg SQ during the first week, 1.2 mg SQ during the second week, and 1.8 mg during the third week and the rest of the treatment). Age, sex, diagnosis time, weight, HbA1c, fasting glucose, systolic and diastolic blood pressure, pharmacological treatment during 6 months were extracted for analysis.

Results: Patients treated with liraglutide 1.8 mg as monotherapy or in conjunction with a therapeutic scheme decreased HbA1c values at 3 and 6 months (1.02%, 95% CI ±0.93, P<0.0001 and 2.08%, 95% CI ±0.8, P<0.0001); fasting glucose at 3 and 6 months (37 mg/dl, 95% CI ±33, P<0.0001 and 68 mg/dl, 95% CI ±26, P<0.0001); weight at 3 and 6 months (3 kg, 95% CI ±10, P<0.0001 and 5 kg, 95% CI ±10, P<0.0001); SBP at 3 and 6 months (9 mmHg, 95% CI ±15, P<0.0001 and 16 mmHg, 95% CI ±16, P<0.0001); and DBP at 3 and 6 months (3 mmHg, 95% CI ±6, P<0.0001 and 6 mmHg, 95% CI ±6, P<0.002). 40% of patients reached HbA1c <7.0; 20% reduction of HbA1c, 39% reduction in fasting blood glucose, 6% reduction in mean weight (1–18%, 1–12 kg), 95% reached SBP <140 mmHg; 100% reached DBP <90 mmHg. Reported adverse events during treatment were nausea (27%), abdominal pain (18%), hypoglycaemia (14%), diarrhoea (9%), and respiratory symptoms (7%). Metformin was present in 65% cases of nausea, 55% cases of diarrhoea, and 43% of cases of abdominal pain. No fatal adverse events occurred.

Conclusion: Patients treated with liraglutide 1.8 mg SQ per day in monotherapy or in conjunction with a therapeutical scheme showed a decrease in HbA1c, fasting glucose, weight, SBP, and DBP during a 6-month treatment.